AUTHORS
Noushin Farnoud, PhD, MASc, Amritha Varshini Varshini Hanasoge Hanasoge Somasundara, PhD2, Christopher Famulare, MS3, Kristin Ammon Shimano, MD4, Ross L. Levine, Prof. Dr.5, Raajit K. Rampal, MD, PhD6, Nicole Kucine, MD, MS7
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, United States
4 University of California San Francisco Benioff Children's Hospital, San Francisco, United States
5 Memorial Sloan Kettering Cancer Center, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, United States
7 Weill Cornell Medicine, New York, United States
ABSTRACT
Introduction:
The classical myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocytosis (ET), prefibrotic myelofibrosis (pre-PMF) and primary myelofibrosis (PMF) are rare clonal disorders characterized by over proliferation of marrow elements, hemostatic complications, and ultimate risk of progression to acute myeloid leukemia. The majority of cases of MPNs in adults are driven by mutations in JAK2, CALR, or MPL, and secondary mutations play a role in risk stratification and prognostication. These conditions are quite rare in young patients, and little is known about the molecular features of these diseases in childhood, nor how they differ from those of older patients. Here we describe the findings of a large sequencing evaluation of a cohort of pediatric MPN patients and an adult comparator cohort.
Methods:
Peripheral blood and/or bone marrow mononuclear cells were collected from 50 pediatric patients with MPNs. DNA was extracted and sequenced using targeted heme malignancy gene panels. Variants were called using a combination of variant callers. For single-nucleotide variants, CaVEMan, Mutect, and Strelka were used, while for small insertions and deletions Pindel was also used. Manual review of mutations was performed when needed. Variant allele frequency (VAF) was uniformly reported across all called variants using a realignment procedure. Likely artifact variants were filtered out based on the number of callers calling a given variant and the combination of filters from the triple callers, and variants with VAF <2% in all samples or less than 3 mutant supporting reads were excluded.
Results:
The median age of the pediatric cohort was 14 years (range 2-21). Of the included pediatric patients, 33 (66%) have ET, 12 (24%) have PV, 3 (6%) have pre-PMF, and 2 (4%) have PMF. When looking at classical drivers of MPNs, 27 (54%) patients have a mutation in JAK2 (2 with JAK2 exon 12 mutations, the rest were JAK2V617F), 7 (14%) had a CALR mutation, 2 (4%) harbored a MPL mutation, and 14 (28%) were triple negative (TN) or lacking a driver in one of the 3 primary driver genes (all TN patients had ET).
A comparator cohort of adult patients with ET and PV who also underwent targeted sequencing (n=233, median age=54 years, range 22-90) showed a higher percentage of JAK2 mutations (n=189, 81%) with few triple negative patients. While multiple TET2 (n=32, 14%) and DNMT3A (n=25, 11%) mutations were seen regularly in the adult cohort, only 1 TET2 mutation (2%) and no DNMT3A mutations were seen in the pediatric cohort. Single hits were found in DNA-repair genes in the pediatric cohort in MSH3, ERCC3, and PMS2 (in JAK2-mutated patients) and ERCC2 (in a triple negative patient). Nine of the 14 children with TN ET had no selected oncogenic or likely oncogenic mutations identified.
Conclusion:
Pediatric cases of classical MPNs show higher rates of triple negative disease and lower rates of JAK2-positivity than adult counterparts. Common CHIP mutations seen in adults were largely absent in the pediatric cohort, and timing of the development of oncogenic mutations in these young patients is a key question. A portion of young patients with triple negative disease did not have any relevant mutations identified indicating further study is needed of this unique population to better understand if they are truly clonal diseases like their counterparts with driver mutations. There is limited data on the molecular profiles of young MPN patients, and this work adds to that small body of literature and highlights the need for further study of the drivers of MPNs in childhood and how they differ from those presenting with disease in adulthood.
DISCLOSURES
Nicole Kucine, MD, MS: Protagonist Therapeutics - Consultancy (Includes expert testimony)